Dexa Group, as a national pharmaceutical company, is committed to meeting the quality of Indonesian natural raw materials as the content of Indonesian Indigenous Modern Medicines, beginning with cultivation, harvesting, and post-harvest processes and continuing through the manufacturing process by Good Traditional Medicine Manufacturing standards (CPOTB). This is necessary to preserve the ecosystem’s consistency for developing natural raw materials and applying phytopharmaceu

The Ministry of Industry continues to improve the competitiveness of the national industry through the transformation towards industry 4.0. In this regard, as a leading international pharmaceutical company in Indonesia, Dexa Group has implemented Industry 4.0 in the production process to distribution. President Director of PT Ferron Par Pharmaceuticals, Mr. Krestijanto Pandji, stated that companies that are able to survive in the industrial era 4.0 are those that are able to